Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by Law.com, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!

X

More On

Glaxo investigating Botox marketing in China

Salespeople allegedly rewarded doctors for prescribing the drug

GlaxoSmithKline is investigating allegations that its Chinese sales personnel inappropriately rewarded doctors for prescribing the company’s Botox drug.

An anonymous tipster told Glaxo earlier this year that between 2004 and 2010, the company’s sales staff in China had been giving doctors cash payments, educational credits, dinners and trips in return for prescribing Botox. According to the Wall Street Journal, internal Glaxo documents show that the company’s local managers instructed salespeople to use their personal email addresses to discuss these marketing strategies. At least 16 members of the China sales staff were involved in the email discussions.

A Glaxo spokesperson told the Journal that the company’s “inquiries to date have found no evidence of bribery or corruption in relation to our sales and marketing of therapeutic Botox in China.” 

Stay tuned for more updates as the story develops. 

For more InsideCounsel stories about pharmaceuticals, read:

FDA rule would allow generic drugmakers to update labels

Walgreens reaches $80 million settlement over painkillers

Government will allow morning after pill to be sold to all ages

FDA allows continued sale of generic Opana painkiller

FDA issues warning about shortened cancer drug name

Generic-drug makers sue brand-name companies for product samples

Ashley Post

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.